{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'All correspondence related to records retention, destruction or transfer of study documents', 'should be sent directly to BioCryst study personnel, copying the email archives@biocryst.com.', '14.6.', 'Confidentiality of Information and Data', \"BioCryst affirms the subject's right to protection against invasion of privacy and secure\", 'maintenance of the confidential nature of their personal data. Only a subject identification', 'number and subject identifiers permitted by local regulation will identify subject data retrieved', 'by BioCryst. However, in compliance with federal regulations, BioCryst requires the Investigator', \"to permit BioCryst's representatives and, when necessary, representatives of the FDA or other\", 'regulatory authorities to review and/or copy any medical records relevant to the study,', 'maintaining pseudo-anonymity.', 'All parties will abide by all applicable laws and regulations regarding subject privacy and', 'confidentiality, including, the Health Insurance Portability and Accountability Act (HIPAA),', 'where this rule is applicable and the requirements of the Data Protection Act in the EU, where', 'applicable. A valid authorization and consent must meet the specifications of the applicable laws', 'and regulations relating to such personal data and health information. It is the responsibility of', 'the Investigator and institution to obtain such waiver/authorization in writing from the', 'appropriate individual. HIPAA authorizations are required for US sites only.', '14.7.', 'Study Publication', 'All data generated from this study are the property of BioCryst and shall be held in strict', 'confidence along with all information furnished by BioCryst. Except as provided through written', 'agreement with BioCryst, independent analysis and/or publication of these data by the', 'Investigator or any member of his/her staff is not permitted. Such consent will not be withheld', 'unreasonably. BioCryst is in agreement with the principle of full disclosure of clinical trial', 'results.', '102']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', '15.', 'REFERENCES', 'Aygoren-Pursun, E., A. Bygum, V. Grivcheva-Panovska, M. Magerl, J. Graff, U. C. Steiner, O.', 'Fain, A. Huissoon, T. Kinaciyan, H. Farkas, R. Lleonart, H. J. Longhurst, W. Rae, M. Triggiani,', 'W. Aberer, M. Cancian, A. Zanichelli, W. B. Smith, M. L. Baeza, A. Du-Thanh, M. Gompels, T.', 'Gonzalez-Quevedo, J. Greve, M. Guilarte, C. Katelaris, S. Dobo, M. Cornpropst, D. Clemons, L.', 'Fang, P. Collis, W. Sheridan, M. Maurer and M. Cicardi (2018). \"Oral Plasma Kallikrein', 'Inhibitor for Prophylaxis in Hereditary Angioedema.\" N Engl J Med 379(4): 352-362.', 'Bork, K., J. Hardt and G. Witzke (2012). \"Fatal laryngeal attacks and mortality in hereditary', 'angioedema due to C1-INH deficiency.\" J Allergy Clin Immunol 130(3): 692-697.', 'Bork, K., G. Meng, P. Staubach and J. Hardt (2006). \"Hereditary angioedema: new findings', 'concerning symptoms, affected organs, and course.\" Am J Med 119(3): 267-274.', 'Bouillet, L., H. Longhurst, I. Boccon-Gibod, K. Bork, C. Bucher, A. Bygum, T. Caballero, C.', 'Drouet, H. Farkas, C. Massot, E. W. Nielsen, D. Ponard and M. Cicardi (2008). \"Disease', 'expression in women with hereditary angioedema.\" Am J Obstet Gynecol 199(5): 484 e481-484.', 'Caballero, T., H. Farkas, L. Bouillet, T. Bowen, A. Gompel, C. Fagerberg, J. Bjokander, K.', 'Bork, A. Bygum, M. Cicardi, C. de Carolis, M. Frank, J. H. Gooi, H. Longhurst, I. Martinez-', 'Saguer, E. W. Nielsen, K. Obtulowitz, R. Perricone, N. Prior and C. I. D. W. Group (2012).', '\"International consensus and practical guidelines on the gynecologic and obstetric management', 'of female patients with hereditary angioedema caused by C1 inhibitor deficiency.\" J Allergy Clin', 'Immunol 129(2) 308-320.', 'Cicardi, M., K. Bork, T. Caballero, T. Craig, H. H. Li, H. Longhurst, A. Reshef, B. Zuraw and', 'Hawk (2012). \"Evidence-based recommendations for the therapeutic management of', 'angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International', 'Working Group.\" Allergy 67(2): 147-157.', 'Cornpropst, M., S. Dobo, J. Collier, A. Rose, R. Wilson, Y. S. Babu, P. Collis and W. Sheridan', '(2016). \"BCX7353, a Potent Inhibitor of Plasma Kallikrein, Shows Sustained Maximal Enzyme', 'Inhibition When Dosed Orally Once Daily: Results from a Phase I Trial in Healthy Subjects.\"', 'Elsevier(AAAAI, Los Angeles).', 'CSL Behring LLC (2017). \"HAEGARDA (C1 Esterase Inhibitor Sucutaneous [Human]) US', \"Prescribing Information.' 7.\", 'DHHS (2010). \"Guidance for Industry - Adaptive Design Clinical Trials for Drugs and Biologics', \"- Draft Guidance.'\", 'Han, E. D., R. C. MacFarlane, A. N. Mulligan, J. Scafidi and A. E. Davis, 3rd (2002). \"Increased', \"vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor.'\", 'J Clin Invest 109(8): 1057-1063.', 'Kaplan, A. P. (2010). \"Enzymatic pathways in the pathogenesis of hereditary angioedema: the', 'role of C1 inhibitor therapy.\" J Allergy Clin Immunol 126(5): 918-925.', 'Kaplan, A. P. and B. Ghebrehiwet (2010). \"The plasma bradykinin-forming pathways and its', 'interrelationships with complement.\" Mol Immunol 47(13): 2161-2169.', 'Longhurst, H. and M. Cicardi (2012). \"Hereditary angio-oedema.\" Lancet 379(9814): 474-481.', '103']\n\n###\n\n", "completion": "END"}